Kancera develops drugs for inflammation and cancer.
Evidence in humans guides clinical Phase IIa study in cardiovascular inflammation. Kancera develops novel drugs that counteract damage during acute & chronic inflammation. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell’s ability to be repaired. Kancera has five drug project...
Kancera develops drugs for inflammation and cancer.
Evidence in humans guides clinical Phase IIa study in cardiovascular inflammation. Kancera develops novel drugs that counteract damage during acute & chronic inflammation. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell’s ability to be repaired. Kancera has five drug projects in the portfolio. Kancera’s main resources are invested in two Fractalkine projects. The further development of the HDAC project is externally financed through agreement with the pharmaceutical company Grünenthal.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.